181 related articles for article (PubMed ID: 21076828)
1. Development of a successful antitumor therapeutic model combining in vivo dendritic cell vaccination with tumor irradiation and intratumoral GM-CSF delivery.
Driessens G; Nuttin L; Gras A; Maetens J; Mievis S; Schoore M; Velu T; Tenenbaum L; Préat V; Bruyns C
Cancer Immunol Immunother; 2011 Feb; 60(2):273-81. PubMed ID: 21076828
[TBL] [Abstract][Full Text] [Related]
2. Highly successful therapeutic vaccinations combining dendritic cells and tumor cells secreting granulocyte macrophage colony-stimulating factor.
Driessens G; Hamdane M; Cool V; Velu T; Bruyns C
Cancer Res; 2004 Nov; 64(22):8435-42. PubMed ID: 15548715
[TBL] [Abstract][Full Text] [Related]
3. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
4. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA
J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012
[TBL] [Abstract][Full Text] [Related]
5. Effects of irradiated tumor vaccine and infusion of granulocyte-macrophage colony-stimulating factor and interleukin-12 on established gliomas in rats.
Chen JC; Chen Y; Wu JM; Su YH; Tai KF; Tseng SH
Cancer Immunol Immunother; 2006 Jul; 55(7):873-83. PubMed ID: 16133106
[TBL] [Abstract][Full Text] [Related]
6. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
7. Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF.
Zhang SN; Choi IK; Huang JH; Yoo JY; Choi KJ; Yun CO
Mol Ther; 2011 Aug; 19(8):1558-68. PubMed ID: 21468000
[TBL] [Abstract][Full Text] [Related]
8. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
[TBL] [Abstract][Full Text] [Related]
9. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells.
Serafini P; Carbley R; Noonan KA; Tan G; Bronte V; Borrello I
Cancer Res; 2004 Sep; 64(17):6337-43. PubMed ID: 15342423
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of an osmotic pump delivered, GM-CSF-based tumor vaccine in the treatment of upper aerodigestive squamous cell carcinoma in rats.
Djalilian HR; Caicedo E; Lessan K; Grami V; Le CT; Spellman SR; Pambuccian S; Hall WA; Low WC; Ondrey FG
Cancer Immunol Immunother; 2007 Aug; 56(8):1207-14. PubMed ID: 17219150
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
Ali SA; McLean CS; Boursnell ME; Martin G; Holmes CL; Reeder S; Entwisle C; Blakeley DM; Shields JG; Todryk S; Vile R; Robins RA; Rees RC
Cancer Res; 2000 Mar; 60(6):1663-70. PubMed ID: 10749137
[TBL] [Abstract][Full Text] [Related]
12. Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.
Mineharu Y; King GD; Muhammad AK; Bannykh S; Kroeger KM; Liu C; Lowenstein PR; Castro MG
Clin Cancer Res; 2011 Jul; 17(14):4705-18. PubMed ID: 21632862
[TBL] [Abstract][Full Text] [Related]
13. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.
Chang EY; Chen CH; Ji H; Wang TL; Hung K; Lee BP; Huang AY; Kurman RJ; Pardoll DM; Wu T
Int J Cancer; 2000 Jun; 86(5):725-30. PubMed ID: 10797297
[TBL] [Abstract][Full Text] [Related]
14. Local tumor irradiation augments the antitumor effect of cytokine-producing autologous cancer cell vaccines in a murine glioma model.
Lumniczky K; Desaknai S; Mangel L; Szende B; Hamada H; Hidvegi EJ; Safrany G
Cancer Gene Ther; 2002 Jan; 9(1):44-52. PubMed ID: 11916244
[TBL] [Abstract][Full Text] [Related]
15. Local administration of granulocyte macrophage colony-stimulating factor induces local accumulation of dendritic cells and antigen-specific CD8+ T cells and enhances dendritic cell cross-presentation.
Lee SJ; Song L; Yang MC; Mao CP; Yang B; Yang A; Jeang J; Peng S; Wu TC; Hung CF
Vaccine; 2015 Mar; 33(13):1549-55. PubMed ID: 25701675
[TBL] [Abstract][Full Text] [Related]
16. Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.
Mitchell DA; Sayour EJ; Reap E; Schmittling R; DeLeon G; Norberg P; Desjardins A; Friedman AH; Friedman HS; Archer G; Sampson JH
Cancer Immunol Res; 2015 Apr; 3(4):320-5. PubMed ID: 25387895
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
[TBL] [Abstract][Full Text] [Related]
18. Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice.
Nagai E; Ogawa T; Kielian T; Ikubo A; Suzuki T
Cancer Immunol Immunother; 1998 Oct; 47(2):72-80. PubMed ID: 9769115
[TBL] [Abstract][Full Text] [Related]
19. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
[TBL] [Abstract][Full Text] [Related]
20. IL-17 is a potent synergistic factor with GM-CSF in mice in stimulating myelopoiesis, dendritic cell expansion, proliferation, and functional enhancement.
Liu B; Tan W; Barsoum A; Gu X; Chen K; Huang W; Ramsay A; Kolls JK; Schwarzenberger P
Exp Hematol; 2010 Oct; 38(10):877-884.e1. PubMed ID: 20600582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
